Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 22Adamax literatureeuropepmc · Observational2026

Diabetes Management Through Glucose Dynamics Analysis Network: A Novel Approach for Accurate Blood Glucose Level Forecasting.

GlucoDiaNet shows promise in predicting blood glucose levels with low error metrics, but further validation in real-world settings is necessary.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the adamax corpus
5
Preclinical
16
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study evaluated a novel hybrid framework called Glucose Dynamics Analysis Network (GlucoDiaNet) for predicting blood glucose levels using the OhioT1DM dataset. The model achieved various error metrics at a 30-minute prediction horizon. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Root Mean Squared Error (RMSE) of 5.2435 mg/dL at 30-min prediction horizon.2026

Abstract

The authors’ words, as europepmc supplied them

Background Accurate real-time prediction of blood glucose (BG) levels is essential for improving insulin-dosing decision support systems, including closed-loop insulin delivery and bolus calculators. However, existing deep learning models often suffer from high computational complexity, limited utilization of physiological factors, and inadequate handling of temporal glucose dependencies. Methods This study proposes Glucose Dynamics Analysis Network (GlucoDiaNet), a hybrid framework for BG prediction integrating spline interpolation for missing value handling, a Dilated Convolutional Residual Network (DilaConv-ResNet) for spatial-temporal feature extraction, Adamax optimization for feature selection and hyperparameter tuning, and a Bidirectional Long Short-Term Memory network for bidirectional sequence learning. The model was evaluated using the OhioT1DM dataset across multiple prediction horizons ranging from 30 to 60 min. Results At the 30-min prediction horizon, GlucoDiaNet achieved a Root Mean Squared Error (RMSE) of 5.2435 mg/dL, Mean Absolute Error (MAE) of 4.3622 mg/dL, R 2 value of 0.9948, and Mean Squared Error (MSE) of 29.3056. The proposed model consistently outperformed baseline models including LSTM, GRU, and TCN across both short- and long-term forecasting tasks while maintaining robust predictive performance at extended prediction intervals. Conclusion GlucoDiaNet effectively enhances blood glucose prediction by integrating efficient preprocessing, deep temporal modeling, and optimization strategies. The proposed framework demonstrates strong potential for future deployment in real-time and wearable diabetes monitoring systems, subject to further hardware-level validation and computational efficiency analysis.

Background

The paper addresses the challenge of accurately forecasting blood glucose levels in diabetes management, a critical aspect for improving patient outcomes. Previous methods may lack precision, leading to suboptimal management of glucose levels. This study proposes a novel approach that could potentially enhance forecasting accuracy, making it relevant for both clinical practice and research.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Adamax corpus

CA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.Nature medicine · 2003 · more than 90% reduction in lesion volume at 14 d post-occlusion in adult miceAnimalBEffects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.JAMA · 2009 · 53.8% decrease in [(11)C]cocaine binding potential in caudate, 95% CI, 43.9% to 63.6%; P < .001HumanAMagnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial.Lancet (London, England) · 2012 · Risk ratio [RR] 1.03, 95% CI 0.85-1.25.HumanBPrevalence, knowledge, attitudes, and practices regarding cognitive enhancer use in a convenience sample of university students in Syria: a cross-sectional study.Annals of medicine · 2026 · n=707 · 14.6% (103/707) reported lifetime CE use.HumanCMgSO<sub>4</sub> alleviates anxiety-like behaviours in mice after traumatic brain injury by inhibiting astrocytic TRPM7 in the amygdala.Journal of psychiatric research · 2026 · Not reported in abstract.AnimalCLactoferrin-modified MSC-derived extracellular vesicles facilitate BBB penetration and enhance gastrodin-induced neuroprotection in Parkinson's disease: involvement of mitophagy.International journal of pharmaceutics: X · 2026 · Achieved a brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice versus undetectable levels for free Gas.Animal